Eli Lilly has outperformed the S&P 500 for five years in a row as Wall Street recognized its huge opportunity in obesity drugs. Six in a row is just not out of the query. Year-to-date performance: Up 33.7% Price-to-earnings ratio: 34.3 in comparison with five-year average of 34.5 Our rating: Buy equivalent 1 Our price goal: $1,000 LLY YTD Mountain Eli Lilly's year-to-date stock performance . '24 Review The dominant theme for Eli Lilly this yr was the launch of its key GLP-1 obesity drug Zepbound, which was approved by the Food and Drug Administration in late 2023. The success was quite remarkable: based on analyst estimates from FactSet, sales needs to be around 5.1 billion US dollars. At the tip of last yr, Wall Street forecast Zepbound revenue of $1.9 billion. Upward corrections of this magnitude explain why the stock followed up its 59 percent jump in 2023 with one other strong yr. Eli Lilly has steadily increased supply of Zepbound and its sister drug Mounjaro, used to treat type 2 diabetes, to ease short-term shortages amid booming demand. But just as importantly, the corporate announced a series of additional production investments, likely one every few months, as an indication of long-term confidence within the GLP-1 market. Given Lilly's decades-long quest to combat Alzheimer's, it's price noting that the corporate's first successful treatment for the memory-robbing disease, Kisunla, was approved in July, even though it hasn't yet made a big contribution to sales. Looking Ahead: Eli Lilly's ability to expand the available supply of Zepbound and Mounjaro in the brand new yr will likely be critical. That seems obvious at first glance, but there may be a more nuanced explanation: removing these products from the FDA's shortage list will impact the power of so-called compounding pharmacies to make unauthorized copies of the drugs. Another area to observe in 2025 is whether or not the FDA expands Zepbound's labeling, which might allow the anti-obesity drug to be prescribed to treat other conditions equivalent to obstructive sleep apnea and increase the danger of heart failure reduce. This would help construct the case for more comprehensive insurance coverage and due to this fact greater revenue opportunities. Updates to Eli Lilly's weight reduction pipeline may be vital, particularly expected late-stage trial results for the obesity pill or Forglipron. Interim results released in June 2023 showed it was highly effective, and Wall Street sees oral versions of obesity treatments as crucial to meeting maximum demand. Zepbound and its foremost competitor Wegovy from Novo Nordisk are taken as an injection once every week. In the approaching yr, investors will likely be keeping an in depth eye on health care policy outside Washington, especially as noted drug industry critic Robert F. Kennedy Jr. awaits confirmation to guide the Department of Health and Human Services. Although Kennedy Jim recently said he sees GLP-1 as a part of the answer to America's obesity crisis, he has often derided the drugs prior to now. Additionally, it’s unclear what the brand new Trump administration might mean for the Biden White House's proposal to expand Medicare and Medicaid access to GLP-1. Positive news from Novo Nordisk and other hopeful challengers like Viking Therapeutics could put pressure on Lilly shares within the near term, but we’re confident the corporate can hold its own, thanks largely to its manufacturing capability benefits. Jim Cramer recently named Eli Lilly one in all the portfolio's 12 core holdings through 2025. (Jim Cramer's Charitable Trust is long-LLY. See a full list of stocks here.) As a subscriber to CNBC Investing Club with Jim Cramer, you’ll receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable foundation's portfolio. If Jim discussed a stock on CNBC television, he waits 72 hours after the trade alert is issued before executing the trade. THE INVESTING CLUB INFORMATION SET FORTH ABOVE IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY, ALONG WITH OUR DISCLAIMER. THERE ARE NO fiduciary duty or duty IN RECEIVING YOUR INFORMATION PROVIDED IN CONNECTION WITH THE INVESTMENT CLUB. NO SPECIFIC RESULTS OR PROFITS ARE GUARANTEED.
Eli Lilly has surpassed that S&P 500 five years in a row when Wall Street recognized its enormous opportunity in obesity drugs. Six in a row is just not out of the query.
image credit : www.cnbc.com